AR014176A1 - Composiciones farmaceuticas de trifosfato de uridina. - Google Patents
Composiciones farmaceuticas de trifosfato de uridina.Info
- Publication number
- AR014176A1 AR014176A1 ARP980106670A ARP980106670A AR014176A1 AR 014176 A1 AR014176 A1 AR 014176A1 AR P980106670 A ARP980106670 A AR P980106670A AR P980106670 A ARP980106670 A AR P980106670A AR 014176 A1 AR014176 A1 AR 014176A1
- Authority
- AR
- Argentina
- Prior art keywords
- utp
- therapeutic
- uridine
- solubility
- aqueous solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Composiciones farmacéuticas de uridina 5-trifosfato (UTP) para el uso en la promocion del aclaramiento mucociliar incrementado de secreciones mucosasretenidas de los conductos respiratorios humanos, oídos medio / interno o senos . Una formulacion Icomprende UTP y solucion acuosa, con una concentracionterapéutica entre 5 y 45 mg/ml, una tonicidad controlada dentro del rango de 250 a 100 mOsM, un pH entre 7,0 y 7,5 y es estéril. La composicion con ajustede pH es capaz de almacenamiento a largo plazo en el estado refrigerado, con un período de vida de hasta 30 meses. La formulacion I puede suministrarse enforma terapéutica ya sea en una forma nebulizada o en una forma líquida. Una formulacion II comprende UTP en una solucion acuosa que tiene una concentracionterapéutica que se acerca al límite de la solubilildad de UTP a temperatura ambiente, o en una suspension que excede la solubilidad de la droga. Esta altaconcentracion permite el suministro de una cantidad terapéutica deUTP en muy pequenos volumenes (50 a 100 omega ) adecuados para la administracion mediantedispositivos portátiles para sostén manual, como inhaladores de dosis medidas. La formulacion II posee un período de vida prolongado sin la necesidad derefrigeracion después de ser dispensada al paciente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/996,740 US5968913A (en) | 1996-07-03 | 1997-12-23 | Pharmaceutical compositions of uridine triphosphate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR014176A1 true AR014176A1 (es) | 2001-02-07 |
Family
ID=25543248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106670A AR014176A1 (es) | 1997-12-23 | 1998-12-23 | Composiciones farmaceuticas de trifosfato de uridina. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5968913A (es) |
| EP (1) | EP1041969B1 (es) |
| JP (1) | JP2001526208A (es) |
| KR (1) | KR20010033310A (es) |
| CN (1) | CN1143672C (es) |
| AR (1) | AR014176A1 (es) |
| AT (1) | ATE235225T1 (es) |
| AU (1) | AU747350B2 (es) |
| BR (1) | BR9814426A (es) |
| CA (1) | CA2316018A1 (es) |
| DE (1) | DE69812708T2 (es) |
| ID (1) | ID26137A (es) |
| IL (1) | IL136895A0 (es) |
| NO (1) | NO20003246L (es) |
| NZ (1) | NZ505821A (es) |
| WO (1) | WO1999032085A2 (es) |
| ZA (1) | ZA9811833B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319908B1 (en) | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
| US5763447C1 (en) | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
| TW593331B (en) | 1997-07-25 | 2004-06-21 | Inspire Pharmaceuticals Inc | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
| US6872710B2 (en) * | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
| CA2295515C (en) | 1997-07-25 | 2006-03-14 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof |
| US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7132408B2 (en) | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US6327215B1 (en) * | 2000-09-28 | 2001-12-04 | Vanguard International Semiconductor Corporation | Local bit switch decode circuit and method |
| AR034635A1 (es) | 2001-06-25 | 2004-03-03 | Inspire Pharmaceuticals Inc | Lubricacion de las articulaciones con agonistas del receptor purinergico p2y |
| WO2003039473A2 (en) * | 2001-11-06 | 2003-05-15 | Inspire Pharmaceuticals, Inc. | Method for treating or preventing inflammatory diseases |
| CN1700894A (zh) * | 2002-10-18 | 2005-11-23 | 莫利化学医药公司 | 使用羊毛硫抗生素治疗干眼病的方法 |
| EP1750740A4 (en) * | 2004-05-06 | 2009-06-10 | Molichem Medicines Inc | TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING COMPOSITIONS CONTAINING LANTIBIOTICS |
| US7479481B2 (en) * | 2004-05-06 | 2009-01-20 | Molichem Medicines, Inc. | Treatment of ocular diseases and disorders using lantibiotic compositions |
| US7368439B2 (en) * | 2005-06-15 | 2008-05-06 | Bar - Ilan University | Dinucleoside poly(borano)phosphate derivatives and uses thereof |
| US20120077778A1 (en) * | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
| EP2556832B1 (en) | 2011-08-12 | 2017-07-19 | Universitätsklinikum Freiburg | Uridine and uridine analogues for use in the treatment of chronic obstructive pulmonary disease |
| US9034442B2 (en) * | 2012-11-30 | 2015-05-19 | Corning Incorporated | Strengthened borosilicate glass containers with improved damage tolerance |
| US10117806B2 (en) * | 2012-11-30 | 2018-11-06 | Corning Incorporated | Strengthened glass containers resistant to delamination and damage |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB916309A (en) * | 1959-12-14 | 1963-01-23 | Ile Auguil Soc Civ | Improvements in and relating to new therapeutic preparation for use as a muscular and nervous stimulant |
| JPS60126220A (ja) * | 1983-12-09 | 1985-07-05 | Otsuka Pharmaceut Factory Inc | 核酸成分組成物 |
| GB9027968D0 (en) * | 1990-12-22 | 1991-02-13 | Fisons Plc | Method of treatment |
| US5164740A (en) * | 1991-04-24 | 1992-11-17 | Yehuda Ivri | High frequency printing mechanism |
| EP0517573A1 (fr) * | 1991-06-05 | 1992-12-09 | Synthelabo | Compositions pharmaceutiques pour le traitement des affections des voies respiratoires |
| FR2677250B1 (fr) * | 1991-06-05 | 1995-01-20 | Synthelabo | Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique. |
| US5292498A (en) * | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
| EP0615470B1 (en) * | 1991-12-04 | 1995-12-13 | The Technology Partnership Public Limited Company | Fluid droplet production apparatus and method |
| US5547131A (en) * | 1992-12-04 | 1996-08-20 | Bespak Plc | Dispensing device with spray nozzle and driven piston |
| US5497763A (en) * | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| US5593824A (en) * | 1994-09-02 | 1997-01-14 | Pharmacia Biotech, Inc. | Biological reagent spheres |
| US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| US6423694B1 (en) * | 1996-02-21 | 2002-07-23 | Inspire Pharmaceuticals, Inc. | Method of treating otitis media with uridine triphosphates and related compounds |
| ATE335492T1 (de) * | 1996-03-27 | 2006-09-15 | Inspire Pharmaceuticals Inc | Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen |
| US5962432A (en) * | 1996-07-03 | 1999-10-05 | Inspire Pharmaceuticals, Inc. | Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate |
| US5789391A (en) * | 1996-07-03 | 1998-08-04 | Inspire Pharmaceuticals, Inc. | Method of treating sinusitis with uridine triphosphates and related compounds |
| US5763447C1 (en) * | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
| US6159952A (en) * | 1996-11-07 | 2000-12-12 | Inspire Pharmaceuticals, Inc. | Method of treating bronchitis with uridine triphosphate and related compounds |
-
1997
- 1997-12-23 US US08/996,740 patent/US5968913A/en not_active Expired - Lifetime
-
1998
- 1998-12-23 KR KR1020007006756A patent/KR20010033310A/ko active IP Right Grant
- 1998-12-23 BR BR9814426-0A patent/BR9814426A/pt not_active IP Right Cessation
- 1998-12-23 ZA ZA9811833A patent/ZA9811833B/xx unknown
- 1998-12-23 JP JP2000525079A patent/JP2001526208A/ja active Pending
- 1998-12-23 CN CNB988136228A patent/CN1143672C/zh not_active Expired - Fee Related
- 1998-12-23 AR ARP980106670A patent/AR014176A1/es not_active Application Discontinuation
- 1998-12-23 AU AU20922/99A patent/AU747350B2/en not_active Ceased
- 1998-12-23 CA CA002316018A patent/CA2316018A1/en not_active Abandoned
- 1998-12-23 WO PCT/US1998/027409 patent/WO1999032085A2/en active IP Right Grant
- 1998-12-23 AT AT98965462T patent/ATE235225T1/de not_active IP Right Cessation
- 1998-12-23 ID IDW20001428A patent/ID26137A/id unknown
- 1998-12-23 EP EP98965462A patent/EP1041969B1/en not_active Expired - Lifetime
- 1998-12-23 DE DE69812708T patent/DE69812708T2/de not_active Expired - Fee Related
- 1998-12-23 IL IL13689598A patent/IL136895A0/xx unknown
- 1998-12-23 NZ NZ505821A patent/NZ505821A/xx unknown
-
2000
- 2000-06-21 NO NO20003246A patent/NO20003246L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ505821A (en) | 2002-09-27 |
| ATE235225T1 (de) | 2003-04-15 |
| AU2092299A (en) | 1999-07-12 |
| IL136895A0 (en) | 2001-06-14 |
| CN1143672C (zh) | 2004-03-31 |
| US5968913A (en) | 1999-10-19 |
| WO1999032085A3 (en) | 1999-09-02 |
| BR9814426A (pt) | 2001-10-23 |
| NO20003246L (no) | 2000-08-23 |
| CN1284861A (zh) | 2001-02-21 |
| DE69812708T2 (de) | 2004-01-29 |
| KR20010033310A (ko) | 2001-04-25 |
| CA2316018A1 (en) | 1999-07-01 |
| JP2001526208A (ja) | 2001-12-18 |
| NO20003246D0 (no) | 2000-06-21 |
| DE69812708D1 (de) | 2003-04-30 |
| WO1999032085A2 (en) | 1999-07-01 |
| ZA9811833B (en) | 1999-07-20 |
| EP1041969B1 (en) | 2003-03-26 |
| EP1041969A2 (en) | 2000-10-11 |
| ID26137A (id) | 2000-11-23 |
| AU747350B2 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR014176A1 (es) | Composiciones farmaceuticas de trifosfato de uridina. | |
| ES2201316T3 (es) | Nuevas formulaciones liquidas estables a base de paracetamol y su modo de preparacion. | |
| ES2208931T3 (es) | Composicion farmaceutica basada en agua. | |
| UY25432A1 (es) | Administracion de un agente activo en aerosol | |
| ES2549766T3 (es) | Compuestos antimicrobianos y métodos para su utilización | |
| PT1320355E (pt) | Sistema para administracao de uma formulacao de tobramicina | |
| ES2229693T3 (es) | Formulaciones de co-disolventes que contienen vitamina d. | |
| BR0214757A (pt) | Formulações farmacêuticas de derivados de platina | |
| ES2414982T7 (es) | Tratamiento a largo plazo de infección por VIH con TCM278 | |
| BR9907866A (pt) | Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia | |
| ES2206880T3 (es) | Suspension acuosa para administracion nasal de loteprednol. | |
| HUT75684A (en) | Parenteral solutions of diclofenac salts | |
| BRPI0719821B1 (pt) | composição estável na armazenagem apropriada para administração a pacientes | |
| RS50664B (sr) | Mehanizam za prikazivanje odabrane doze za primenu kod naprava za unošenje medikamenata u telo pacijenta | |
| AR030253A1 (es) | Sistemas de suministro de drogas autoemulsionantes para drogas lipofilicas extremadamente insolubles en agua, una formulacion y el uso de una composicion para la fabricacion de un medicamento | |
| ES2764506T3 (es) | Composición que contiene cineol para administración nasal | |
| AR047108A1 (es) | Formulacion farmaceutica para tratar afecciones vaginales en humanos, composicion para tratar una infeccion vaginal y metodo para tratar dicha infeccion vaginal | |
| ES2860098T3 (es) | Composición para la aplicación nasal | |
| ES2281021T3 (es) | Formulacion liquida que contiene tobramicina. | |
| ES2392097T3 (es) | Preparaciones inyectables de diclofenaco y sus sales farmacéuticamente aceptables | |
| ES2255977T3 (es) | Utilizacion de un compuesto farmaceutico que contiene desoxipeganina para el tratamiento de la dependencia a la nicotina. | |
| ES2686299T3 (es) | Composiciones nasales de vitamina B12 | |
| ES2973258T3 (es) | Sistema de vacunación nasal contra la gripe | |
| ES2198424T3 (es) | Soluciones inyectables listas para el empleo que contienen doxorrubicina. | |
| ES2595257T3 (es) | Mejoras en o relativas a composiciones de apomorfina bucofaríngeas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |